UBS Group’s NLS Pharmaceutics Warrant NLSPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-424
| Closed | -$8 | – | 10965 |
|
|
2025
Q3 | $8 | Buy |
+424
| New | +$7 | ﹤0.01% | 10205 |
|
|
2024
Q2 | – | Sell |
-6,023
| Closed | -$295 | – | 9915 |
|
|
2024
Q1 | $295 | Buy |
6,023
+5,023
| +502% | +$288 | ﹤0.01% | 8645 |
|
|
2023
Q4 | $55 | Buy |
+1,000
| New | +$99 | ﹤0.01% | 8984 |
|
|
2023
Q1 | – | Sell |
-3,745
| Closed | -$1.09K | – | 10100 |
|
|
2022
Q4 | $1.09K | Sell |
3,745
-11,802
| -76% | -$2.09K | ﹤0.01% | 9963 |
|
|
2022
Q3 | $4K | Buy |
15,547
+13,461
| +645% | +$2.77K | ﹤0.01% | 9376 |
|
|
2022
Q2 | $0 | Buy |
2,086
+96
| +5% | +$23 | ﹤0.01% | 10714 |
|
|
2022
Q1 | $1K | Sell |
1,990
-645
| -24% | -$229 | ﹤0.01% | 9890 |
|
|
2021
Q4 | $1K | Hold |
2,635
| – | – | ﹤0.01% | 10005 |
|
|
2021
Q3 | $2K | Sell |
2,635
-711
| -21% | -$658 | ﹤0.01% | 8971 |
|
|
2021
Q2 | $3K | Buy |
3,346
+227
| +7% | +$201 | ﹤0.01% | 8824 |
|
|
2021
Q1 | $3K | Buy |
+3,119
| New | +$2.84K | ﹤0.01% | 8527 |
|
UBS Group's NLSPW Position: Q4 2025 in Review
UBS Group sold out of NLS Pharmaceutics Warrant (NLSPW) in Q4 2025, closing a stake of 424 shares — an estimated $8 sold.
UBS Group first reported a position in NLSPW in Q1 2021 and held it in 11 quarters. The position peaked at $4K in Q3 2022. 0 funds tracked by Wall St. Rank hold NLSPW as of Q4 2025.
- UBS Group reported no remaining NLS Pharmaceutics Warrant position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 424 NLS Pharmaceutics Warrant shares in Q4 2025, an estimated $8.
- UBS Group first reported a position in NLS Pharmaceutics Warrant in Q1 2021 and held it in 11 quarters.
- UBS Group's NLS Pharmaceutics Warrant position peaked at $4K in Q3 2022.
- 0 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.